Latest News:  Landos Biopharma Completes $60 Million Series B Financing

About Xontogeny

Xontogeny (zon-TOJ-uh-nee) is a biotech aggregator with a differentiated business model to support the accelerated development of life science technologies in the pursuit of helping patients with serious diseases. Specifically, we partner with entrepreneurs, providing the leadership and operating experience needed to increase the probability of success with early drug and technology development.

At Xontogeny, we believe that scientific founders supply the passion and determination integral to the success of their companies. While the foundation of success is good science, how that science is developed from inception to maturity serves as the critical pathway. Therefore, we focus on supporting the entrepreneur’s pursuit and optimizing the development pathway with an exceptionally talented and experienced operational team. With our team’s track record of success, entrepreneurs of affiliated companies will gain the support and guidance they need while remaining lean, virtual, and without the financial burden of supporting a full-time team.

This dynamic model has the additional benefit of supporting the goals of the founding scientists and entrepreneurs to retain more control and equity, while increasing the chance of accessing investment, and ultimately development success.


We believe that founders are crucial to the success of a development program. We seek to support and guide scientific entrepreneurs through an optimized development pathway with an experienced operational team.

Learn More...

Industry Professionals

We believe that sub-optimal program design and poor execution play a substantial role in the high failure rate associated with the biopharma industry. As such, we believe that an exceptionally talented and experienced operational team can help increase the odds of success.

Learn More...


Chris Garabedian

Chairman and CEO

Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. Learn More...

Fred Callori

SVP, Corporate Development

Fred Callori joined Xontogeny in September 2017 to support the company’s strategic and operational objectives, including providing overall corporate governance, transactional, and strategic advice to Xontogeny’s portfolio of companies. Learn More...

Joseph Edelman


Joseph Edelman founded Perceptive Advisors, LLC in 1999, a hedge fund focused on supporting the progress of the life sciences industry. Learn More...

Adam Stone


Adam Stone joined Perceptive Advisors, a hedge fund focused on supporting the progress of the life sciences industry, in 2006. Learn More...

Privacy Preference Center


The NID, DSID, IDE cookies are set by DoubleClick (which is owned by Google) to help build a profile of your interests and show you relevant ads on other sites. The other cookies (from carry out information about how the end user uses the website and any advertising that the end user may have seen before visiting the said website.



Xontogeny uses these cookies to collect information about how visitors use our Site. We use the information to compile reports and to help us improve the Site. The cookies collect information in an anonymous form, including the number of visitors to the Site, where visitors have come to the Site from and the pages they visited. If you do not allow these cookies we will not be able to include your visit in our statistics. You can read the full Google Analytics privacy policy at:

_ga,_gat,_gid, _gali


The OGPC cookie enables the functionality of Google Maps. s_cc Adobe Site Catalyst cookie, determines whether cookies are enabled in the browser. The s_sq and s_vi, Adobe Site Catalyst cookie, stores information about the previous link clicked within the site as well as identify unique visitors, with an ID and timestamp.

OGPC, s_cc, s_sq, s_vi